Clinical Comparisons Between SMART and Historical ICS-SABA Therapy
| Regimen | Inhaler Formulation | Age Group (Years) | Dosing | Maximum Daily Dose | Clinical Pearl | |
|---|---|---|---|---|---|---|
| Maintenance | Reliever | |||||
| Budesonide-Formoterol (SMART) | MDI | Children 4 to 11 | 80-4.5 µg (1 puff) Once Daily | 80-4.5 µg (1 puff) PRN | 8 Inhalations | Patients do not need to rinse their mouth following as-needed inhalations |
| Adults & Adolescents 12+ | 160-4. 5 µg (1 puff) Once or Twice Daily | 160-4.5 µg (1 puff) PRN | 12 Inhalations | |||
| Budesonide & Albuterol (ICS-SABA) | Flexhaler & HFA | Children 4 to 11 | 180 µg (1 puff) Twice Daily (Budesonide) | 180 µg (2 puffs) PRN (Albuterol) | 360 µg (Budesonide) | Do not shake the FlexhalerUse both inhalers to treat acute asthma symptoms |
| Adults & Adolescents 12+ | 180 µg (1 puff) Twice Daily (Budesonide) | 180 µg (2 puffs) PRN(Albuterol) | 720 µg (Budesonide) | |||
Abbreviations: MDI, Metered-Dose Inhaler; HFA, Hydroflouroalkane; PRN, As-needed; SMART, Single Maintenance and Reliever Therapy; ICS-SABA, ICS monotherapy plus short-acting b -agonists.